Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 1.00 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 1.00 |
| ▸ | ECE1 | P42892 | 2/20 | 1.00 |
| ▸ | MUS81 | Q96NY9 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MGAM | O43451 | 1/20 | 0.62 |
| ▸ | SI | P14410 | 1/20 | 0.62 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.60 |
| ▸ | ALPL | P05186 | 1/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.60 |
| ▸ | ALPG | P10696 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dynasore SCHEMBL16342920 | 1.00 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL30917221 | 1.00 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL29695524 | 1.00 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL847982 | 1.00 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL30961945 | 1.00 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL29385895 | 1.00 | DNM1 (1.00) | DNM1ECE2ECE1MUS81NTRK1 | |
| Dynasore SCHEMBL29435816 | 0.99 | DNM1 (0.97) | DNM1ECE2ECE1MUS81NTRK1 | |
| SCHEMBL14983909 | 0.90 | DNM1 (0.82) | DNM1ECE2ECE1MUS81NTRK1 | |
| SCHEMBL25474226 | 0.88 | DNM1 (0.79) | DNM1ECE2ECE1MUS81NTRK1 | |
| SCHEMBL18876543 | 0.88 | DNM1 (0.79) | DNM1ECE2ECE1MUS81NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379030-A1 | INHIBITORS OF INTRACELLULAR INVASION | DUKE UNIVERSITY | 2021-12-09 | — | — | US | disclosed |
| US-11123333-B2 | Inhibitors of intracellular invasion | MEHARRY MEDICAL COLLEGE (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210196732-A1 | Drug Targets of Delayed Aging and Human Brain Diseases | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
| US-10987367-B2 | Drug targets of delayed aging and human brain diseases | TEXAS TECH UNIVERSITY SYSTEM (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS (US) | 2020-04-02 | — | — | US | disclosed |
| EP-2911692-B1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | UNIV QUEENSLAND (AU) | 2019-08-21 | — | — | EP | disclosed |
| US-20190175565-A1 | INHIBITORS OF INTRACELLULAR INVASION | DUKE UNIVERSITY | 2019-06-13 | — | — | US | disclosed |
| US-10253107-B2 | Use of endocytosis inhibitors and antibodies for cancer therapy | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-04-09 | — | — | US | disclosed |
| US-20170144965-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS | 2017-05-25 | — | — | US | disclosed |
| WO-2015188130-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS (US) | 2015-12-10 | — | — | WO | disclosed |
| EP-2341913-B1 | METHOD OF ENHANCING TGF-BETA SIGNALLING | UNIV SAINT LOUIS (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8809386-B2 | Use of dynamin ring stabilizers | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2014-08-19 | — | — | US | disclosed |
| US-8809386-B2 | Use of dynamin ring stabilizers | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2014-08-19 | — | — | US | disclosed |
| US-8487006-B2 | Method of enhancing TGF-β signalling | AUXAGEN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487006-B2 | Method of enhancing TGF-β signalling | AUXAGEN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100075923-A1 | METHOD OF ENHANCING TGF-BETA SIGNALLING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-25 | — | — | US | disclosed |
| US-20100075923-A1 | METHOD OF ENHANCING TGF-BETA SIGNALLING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-25 | — | — | US | disclosed |
| WO-2010033507-A1 | METHOD OF ENHANCING TGF-BETA SIGNALLING | ST. LOUIS UNIVERSITY (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | COIL, MUC1, MAN2B2 | DNM1 3539/4885ECE2 4633/4885ECE1 4257/4885 |
| US-10987367-B2 | Drug targets of delayed aging and human brain diseases | DNM1L, DNM1, DNM2 | DNM1 2/4885ECE2 1930/4885ECE1 1427/4885 |
| US-10253107-B2 | Use of endocytosis inhibitors and antibodies for cancer therapy | CLINT1, CLTC, DNM1L | DNM1 4/4885ECE2 1743/4885ECE1 869/4885 |
| US-20100075923-A1 | METHOD OF ENHANCING TGF-BETA SIGNALLING | TGFB1, TGFB2, CLTA | DNM1 269/4885ECE2 521/4885ECE1 524/4885 |
| US-20190175565-A1 | INHIBITORS OF INTRACELLULAR INVASION | GDI2, GDI1, RHOT2 | DNM1 23/4885ECE2 3259/4885ECE1 3052/4885 |
| US-20170144965-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | COIL, MUC1, MAN2B2 | DNM1 3453/4885ECE2 4650/4885ECE1 4299/4885 |
| US-20210379030-A1 | INHIBITORS OF INTRACELLULAR INVASION | GDI2, GDI1, RHOT2 | DNM1 23/4885ECE2 3259/4885ECE1 3052/4885 |
| US-20210196732-A1 | Drug Targets of Delayed Aging and Human Brain Diseases | DNM1L, DNM1, DNM2 | DNM1 2/4885ECE2 1046/4885ECE1 1258/4885 |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | DNM1L, DNM1, DNM2 | DNM1 2/4885ECE2 1084/4885ECE1 760/4885 |
| US-11123333-B2 | Inhibitors of intracellular invasion | GDI2, GDI1, RHOT2 | DNM1 23/4885ECE2 3259/4885ECE1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.